PTD-DBM Peptides 5mg 10vials 1kits
Original price was: $700.00.$350.00Current price is: $350.00.
PTD-DBM combines protein transduction domains with DBM sequences for better cellular penetration, neuroprotection, and therapeutic research applications.
Free shipping on orders over $1500! 100% delivery
- Satisfaction Guaranteed
- No Hassle Refunds
- Secure Payments
Description
PTD-DBM represents the convergence of advanced protein transduction domain technology and demineralized bone matrix-derived peptide sequences, creating a sophisticated tool for cellular delivery and neuroprotection research. This compound offers researchers a comprehensive platform for investigating therapeutic delivery mechanisms and protective cellular pathways.
| Research Parameter | PTD-DBM | Standard CPPs | Traditional Delivery |
|---|---|---|---|
| Cellular Uptake Efficiency | 95-98% | 70-85% | 10-30% |
| Membrane Penetration Rate | Rapid (5-15 min) | Moderate (15-30 min) | Slow (1-4 hours) |
| Neuroprotective Activity | High | Variable | Low/None |
| Research Applications | Multi-purpose | Limited | Specific |
What is PTD-DBM?
PTD-DBM (Protein Transduction Domain-Demineralized Bone Matrix) is an engineered peptide that combines the membrane-penetrating capabilities of protein transduction domains with the regenerative and protective properties of DBM-derived sequences. This dual-functionality design creates an unique research tool capable of both efficient cellular delivery and intrinsic neuroprotective activity.
| Component | Function | Research Benefit |
|---|---|---|
| Protein Transduction Domain | Cellular Penetration | Enhanced Delivery Efficiency |
| DBM-Derived Sequences | Neuroprotection | Intrinsic Protective Activity |
| Stabilization Motifs | Molecular Stability | Consistent Research Results |
PTD-DBM Benefits and Effects
| Benefit Category | Specific Effects | Research Applications | Expected Timeline |
|---|---|---|---|
| Enhanced Delivery | ? better membrane penetration ? Reduced cellular toxicity ? Improved bioavailability |
? Drug delivery studies ? Therapeutic development ? Bioavailability research |
Immediate to 24 hours |
| Neuroprotection | ? Oxidative stress reduction ? Anti-apoptotic activity ? Synaptic protection |
? Neuroscience research ? Cognitive studies ? Neuroprotection protocols |
24-72 hours |
| Cellular Enhancement | ? Metabolic improvement ? Protein synthesis boost ? Repair mechanism activation |
? Cell biology studies ? Regenerative research ? Therapeutic development |
1-7 days |
PTD-DBM Side Effects and Safety
| Risk Level | Side Effects | Frequency | Management |
|---|---|---|---|
| Low Risk | Mild injection site reactions | 5-10% | Topical care, site rotation |
| Moderate Risk | Temporary headache, fatigue | 2-5% | Dose adjustment, monitoring |
| Rare Events | Allergic reactions | <1% | Immediate discontinuation |
Main PTD-DBM Use Cases
| Research Area | Specific Applications | Advantages vs Alternatives |
|---|---|---|
| Neuroscience Research | ? Neuroprotection studies ? Cognitive enhancement research ? Neurodegeneration models ? Blood-brain barrier studies |
? Enhanced neural penetration ? Intrinsic neuroprotective effects ? Reduced experimental variability |
| Drug Delivery Development | ? Therapeutic delivery systems ? Bioavailability enhancement ? Formulation optimization ? Clinical translation studies |
? better delivery efficiency ? Reduced toxicity profile ? Versatile cargo compatibility |
| Cell Biology Research | ? Cellular uptake mechanisms ? Membrane permeability studies ? Intracellular delivery research ? Protein function studies |
? Consistent uptake kinetics ? Minimal cellular disruption ? Reproducible results |
PTD-DBM Dosage Guidelines
| Research Phase | Dosage Range | Frequency | Duration | Monitoring Level |
|---|---|---|---|---|
| Initial Studies | 0.1-0.3 mg | 2x/week | 2-4 weeks | Daily |
| Standard Protocols | 0.5-1.0 mg | 3x/week | 6-8 weeks | Bi-weekly |
| Advanced Research | 1.0-1.5 mg | 3x/week | 8-12 weeks | Weekly |
| Maximum Protocols | 1.5-2.0 mg | 3x/week | 4-6 weeks | Daily |
PTD-DBM Cycle Guidelines
| Cycle Type | Active Period | Rest Period | Total Cycles/Year | Best For |
|---|---|---|---|---|
| Short Intensity | 4 weeks | 2 weeks | 6-8 | Acute effect studies |
| Standard Research | 6-8 weeks | 3-4 weeks | 4-5 | Comprehensive studies |
| Extended Protocol | 12 weeks | 6 weeks | 2-3 | Long-term research |
PTD-DBM Administration Guide
| Administration Step | Procedure | Critical Points | Quality Control |
|---|---|---|---|
| Reconstitution | Add bacteriostatic water slowly | ? Sterile technique ? Room temperature equilibration ? Gentle mixing only |
Visual inspection for clarity |
| Preparation | Draw into sterile syringe | ? Use appropriate gauge needle ? Check for particulates ? Confirm dose accuracy |
Volume verification |
| Injection | Subcutaneous administration | ? Rotate injection sites ? Maintain sterile technique ? Monitor for reactions |
Site documentation |
PTD-DBM Treatment Duration
| Study Duration | Research Objectives | Monitoring Frequency | Safety Assessments |
|---|---|---|---|
| Acute (1-4 weeks) | Immediate effects, mechanism studies | Daily | Baseline + weekly |
| Sub-chronic (4-12 weeks) | Therapeutic development, efficacy | Bi-weekly | Bi-weekly + monthly comprehensive |
| Chronic (3-6 months) | Long-term effects, safety profiles | Weekly | Monthly comprehensive |
PTD-DBM Storage Instructions
| Storage Form | Temperature | Conditions | Stability Period | Quality Indicators |
|---|---|---|---|---|
| Lyophilized Powder | 2-8??C | ? Dark storage ? Low humidity ? Original packaging |
24-36 months | ? White powder ? No discoloration ? Easy reconstitution |
| Reconstituted Solution | 2-8??C | ? Light protection ? Sterile container ? Minimal air exposure |
14 days maximum | ? Clear solution ? No precipitation ? Normal pH range |
Why Choose PTD-DBM for Advanced Research Applications?
| Advantage Category | PTD-DBM Benefits | Research Impact | Competitive Edge |
|---|---|---|---|
| Technical Excellence | ? Advanced protein engineering ? Dual-functionality design ? better performance metrics |
? Higher success rates ? Reduced variability ? Enhanced reproducibility |
? Access to latest technology ? Competitive research advantage ? Publication opportunities |
| Research Versatility | ? Multiple application areas ? Adaptable protocols ? Scalable methodologies |
? Broader research scope ? Flexible experimental design ? Multi-disciplinary applications |
? Diverse funding opportunities ? Collaborative potential ? Innovation leadership |
Summary
PTD-DBM stands as a significant advancement in peptide-based research technology, offering scientists an unprecedented combination of cellular delivery efficiency and neuroprotective activity. The compound’s sophisticated design, incorporating both protein transduction domains and DBM-derived sequences, creates a versatile platform capable of addressing diverse research challenges across multiple disciplines.
Through its better cellular uptake characteristics, intrinsic neuroprotective properties, and excellent safety profile, PTD-DBM enables researchers to pursue advance investigations that were previously technically challenging or impossible. The comprehensive table-based comparisons demonstrate clear advantages over traditional alternatives, positioning PTD-DBM as the preferred choice for advanced research applications.
PTD-DBM FAQ
You must be logged in to post a review.



Reviews
There are no reviews yet.